Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Minnesota Clinical Study Center

Neither a doctor nor a teaching hospital

Research payments

$3,576,302

325 payments

Through program year 2025, Minnesota Clinical Study Center is reported as receiving $3,576,302 in research payments, across 325 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $246,180 44
2024 Research $320,565 34
2023 Research $369,612 39
2022 Research $444,933 43
2021 Research $785,516 47
2020 Research $303,267 40
2019 Research $1,106,229 78

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $739,748 12 payments
  2. AbbVie, Inc. $722,384 115 payments
  3. Novartis Pharmaceuticals Corporation $632,798 6 payments
  4. Incyte Corporation $521,782 85 payments
  5. Sun Pharmaceutical Industries Inc. $230,568 18 payments
  6. Aclaris Therapeutics, Inc. $185,399 40 payments
  7. E.R. Squibb & Sons, L.L.C. $168,746 8 payments
  8. Celgene Corporation $114,919 2 payments
  9. Almirall LLC $98,597 8 payments
  10. Acrotech Biopharma LLC $55,652 13 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $541,433 2 payments
  2. Interchangeability Study - ABP 654 $522,204 3 payments
  3. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $229,504 17 payments
  4. Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata $222,312 16 payments
  5. A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) $167,898 6 payments
  6. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo $153,774 17 payments
  7. Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo $137,232 18 payments
  8. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $135,689 19 payments
  9. M15-997 $135,474 20 payments
  10. P3 switching study PK; plaque psoriasis $133,677 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record